ArticleFrontiers in oncology2022

A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT).

Sólrún Melkorka Maggadóttir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.